Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

tirzepatide — the ingredient in the weight loss drug Zepbound and the diabetes drug Mounjaro — along with other drugs used for weight loss. Syringes, alcohol preps, mailers and other ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

“The term osteoporosis screening refers to use of bone density, x-ray studies or other tools to identify persons at an increased risk of fractures or bone breaks,” Dr. Thomas Weber, an endocrinologist ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Commenting on the commission, Dr Kath McCullough, special adviser on obesity at the Royal College of Physicians, said: “For too long, we’ve relied on BMI as a simple measure of obesity, which has ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.

Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...